EGF and hepatocellular carcinoma: In another study, phaP-fused human a1-acid glycoprotein (hAGP) or human epidermal growth factor (hEGF) ligands were attached to the surface of PHB-co-3HHx nanoparticles loaded with RBITC as a model drug, and were then evaluated in vitro against macrophage and hepatocellular carcinoma cells (Bel7402) [52].